Di Wenjuan, Xu Haotian, Xue Ting, Ling Chunhua
Department of Respiratory and Critical Care Medicine, The First Hospital Affiliated of Soochow University, Suzhou City, Jiangsu Province, People's Republic of China.
Cancer Manag Res. 2021 Nov 4;13:8317-8327. doi: 10.2147/CMAR.S328918. eCollection 2021.
According to the most recent data from the National Cancer Center, venous thromboembolism (VTE) has unsurprisingly become one of the most common complications in lung cancer. VTE not only interferes with the equilibrium of the clotting system but it also affects tumor progression and prognosis. For the identification of high-risk patients, many clinical risk assessment models have been developed and validated based on the risk factors found in previous studies. In this review, we will summarize advances in prediction and risk assessment of VTE, with a focus on early diagnosis and therapy, reduction of mortality, and the burden of medical costs in lung cancer patients.
根据国家癌症中心的最新数据，静脉血栓栓塞（VTE）不出所料地成为肺癌最常见的并发症之一。VTE不仅会干扰凝血系统的平衡，还会影响肿瘤进展和预后。为了识别高危患者，基于以往研究中发现的风险因素，已经开发并验证了许多临床风险评估模型。在这篇综述中，我们将总结VTE预测和风险评估方面的进展，重点关注肺癌患者的早期诊断和治疗、降低死亡率以及医疗成本负担。
